ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Hong Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0323-5190; OpenAlex author ID A5122851452. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 trial · 2024: none · 2025: none · 2026: 1 paper

Papers 1

A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. Co-author DOI 10.1186/s12967-026-07723-z ↗

Trials 1

MSLN-targeted CAR-T Cells in Solid Tumors. Principal investigator NCT05783089 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wei Song · 1 shared paper, 2026 · strength 0.26
- Paper A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. DOI 10.1186/s12967-026-07723-z ↗
Fu Xu · 1 shared paper, 2026 · strength 0.26
- Paper A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. DOI 10.1186/s12967-026-07723-z ↗
Yiyao Zhang · 1 shared paper, 2026 · strength 0.26
- Paper A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. DOI 10.1186/s12967-026-07723-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.